ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO470

FGF-23, Hypertension, and Dyslipidemia in Glomerular Disease

Session Information

Category: Hypertension and CVD

  • 1401 Hypertension and CVD: Epidemiology, Risk Factors, and Prevention

Authors

  • Sethna, Christine B., Cohen Children's Medical Center of NY, New Hyde Park, New York, United States
  • Leonard, Mary B., Stanford School of Medicine, Stanford, California, United States
  • Meyers, Kevin E.C., The Children Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Brady, Tammy M., Johns Hopkins University , Baltimore, Maryland, United States
  • Hoofnagle, Andrew N., University of Washington, Seattle, Washington, United States
  • Wolf, Myles, Duke University, Durham, North Carolina, United States
  • Denburg, Michelle, The Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Background

Fibroblast growth factor-23 (FGF-23) has direct effects on vasculature and myocardium and is a risk factor for cardiovascular disease (CVD); however, the impact on CVD in glomerular disease (GD) has not been addressed.

Methods

Plasma intact FGF-23, casual blood pressure (BP) and serum lipids were measured cross-sectionally in Nephrotic Syndrome Study Network (NEPTUNE) participants. Multiple regression analyzed the association of FGF-23 with BP and lipids adjusted for age, sex, black race, glomerular diagnosis, estimated glomerular filtration rate (eGFR), urine protein:creatinine (UPC), obesity and phosphorus (+ height in BP models). FGF-23 was divided into tertiles (<100,≥170 pg/ml). Hypertension (HTN) was defined as BP ≥130/80 mmHg for adults and per established definitions in children (Flynn 2017). BP index (BPi) was calculated as BP÷130/80 for adults and 95th %tile for children. Dyslipidemia (DLP) was defined as abnormal triglycerides, HDL or non-HDL for age (AHA 2013, Daniels 2011).

Results

204 adults (46±16 yr, 60% M, 23% black) and 93 children (9.6±5 yr, 59% M, 42% black) with median eGFR of 78.4 (IQR 50,104.9) ml/min/1.73m2 and UPC 1.83 (IQR 0.57,3.8) were evaluated. Diagnoses included membranous 17%, minimal change 24%, FSGS 33% and IgA 14%. Median FGF-23 was 73 (IQR 50,110) pg/ml, PTH 38 (IQR 26,59) pg/ml and phosphorus 3.9 (IQR 3.4,4.4) mg/dl. HTN was present in 68% and DLP in 75%; mean SBPi was 0.83±0.15 and DBPi 0.94±0.18. The highest tertile of FGF-23 was associated with HTN, SBP, DBP, SBPi and DBPi, vs. the lowest tertile in adjusted models (Table 1). FGF-23 was not associated with DLP.

Conclusion

In NEPTUNE, FGF-23 was directly associated with HTN and BP. Further study of FGF-23 as a therapeutic target for reducing CVD in GD is warranted.

Funding

  • Other NIH Support